Insider Trading Alert - AMRI, STT And MLNX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 5, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $54.87 to $138,948,169.00.

Highlighted Stocks Traded by Insiders:

Albany Molecular Research (AMRI) - FREE Research Report

Cable Stuart M, who is 10% Owner at Albany Molecular Research, sold 30,000 shares at $15.98 on May 5, 2014. Following this transaction, the 10% Owner owned 4.3 million shares meaning that the stake was reduced by 0.7% with the 30,000-share transaction.

The shares most recently traded at $16.08, up $0.10, or 0.62% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 10,300

The average volume for Albany Molecular Research has been 658,400 shares per day over the past 30 days. Albany Molecular Research has a market cap of $504.3 million and is part of the health care sector and drugs industry. Shares are up 58.73% year-to-date as of the close of trading on Monday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 39.0. Currently, there is 1 analyst who rates Albany Molecular Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

State Street (STT) - FREE Research Report

Quirk Alison A., who is Executive Vice President at State Street, sold 3,308 shares at $64.66 on May 5, 2014. Following this transaction, the Executive Vice President owned 112,539 shares meaning that the stake was reduced by 2.86% with the 3,308-share transaction.

Kuritzkes Andrew P, who is EVP and Chief Risk Officer at State Street, sold 26,133 shares at $64.53 on May 5, 2014. Following this transaction, the EVP and Chief Risk Officer owned 128,547 shares meaning that the stake was reduced by 16.89% with the 26,133-share transaction.

The shares most recently traded at $63.77, down $0.76, or 1.19% since the insider transaction. Historical insider transactions for State Street go as follows:

  • 4-Week # shares sold: 25,388
  • 12-Week # shares sold: 52,240
  • 24-Week # shares sold: 80,448

The average volume for State Street has been 3.0 million shares per day over the past 30 days. State Street has a market cap of $28.2 billion and is part of the financial sector and financial services industry. Shares are down 12.62% year-to-date as of the close of trading on Monday.

State Street Corporation provides various financial services and products to institutional investors worldwide. The stock currently has a dividend yield of 1.59%. The company has a P/E ratio of 14.7. Currently, there are 9 analysts who rate State Street a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STT - FREE

TheStreet Quant Ratings rates State Street as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full State Street Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mellanox Technologies (MLNX) - FREE Research Report

Shulman Yakov (Jacob), who is Chief Financial Officer at Mellanox Technologies, sold 2,036 shares at $34.75 on May 5, 2014. Following this transaction, the Chief Financial Officer owned 34,140 shares meaning that the stake was reduced by 5.63% with the 2,036-share transaction.

The shares most recently traded at $34.00, down $0.75, or 2.21% since the insider transaction. Historical insider transactions for Mellanox Technologies go as follows:

  • 4-Week # shares bought: 57,739
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 57,739
  • 12-Week # shares sold: 11,167
  • 24-Week # shares bought: 57,739
  • 24-Week # shares sold: 21,116

The average volume for Mellanox Technologies has been 488,400 shares per day over the past 30 days. Mellanox Technologies has a market cap of $1.5 billion and is part of the technology sector and electronics industry. Shares are down 15.31% year-to-date as of the close of trading on Monday.

Mellanox Technologies, Ltd., a fabless semiconductor company, designs, manufactures, and sells interconnect products and solutions. Currently, there are 4 analysts who rate Mellanox Technologies a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MLNX - FREE

TheStreet Quant Ratings rates Mellanox Technologies as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Mellanox Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing